Share Name Share Symbol Market Type Share ISIN Share Description
Evocutis LSE:EVO London Ordinary Share GB00B4WKYH05 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.0425 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.00 0.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services -0.37 -0.07 1
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Evocutis (EVO) Latest News

Real-Time news about Evocutis (London Stock Exchange): 0 recent articles
More Evocutis News
Evocutis Takeover Rumours

Evocutis (EVO) Discussions and Chat

Evocutis (EVO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Evocutis trades in real-time

Evocutis (EVO) Top Chat Posts

ryan83: agree m4, its about Nutech report, probably because it started to get ramped yesterday! but as you say, no value for HH in teh EVO price at the moment.
bobby.ifa: Does anyone know the share price that we acquired the Venn Life sciences group for last year, presently trading 20-21p
crimsonb: Now make sure you are aware about 2 things- value and share price. These two have different meanings. So in 2 weeks time share price might increase to 0.32 or more, but I am not so sure about the value... We will see.
hedgehog 100: 20/01/2015 16:57 UKREG Evocutis PLC Final Results "Final results for the year ended 31 July 2014 Chairman's Report Overview This has been an eventful year for the Company which has seen the transition from a trading company to an investing company. During the first eight months of the financial year, the Company was focussed on disposing of its intellectual property assets and in closing down its trading operations in Wetherby. These activities were concluded in March 2014 with the sale of LabSkin(TM) , SYN1113 and other related intellectual property to Venn Life Science Holdings plc. The sale provided for an element of contingent consideration relating to a stake in any future commercialisation of the intellectual property by Venn in the form or royalties paid on revenues generated from those assets. Following the cessation of trading operations, the Company has been an investing company. The Company's principal assets are a cash balance and available-for-sale investments in the form of shares in Venn Life Science Holdings plc. The Board Following our shareholder meeting on 12 September 2014, the directors who previously managed the trading operation of the Group stepped down from the board and myself, along with Donald Strang and Hamish Harris were appointed to take responsibility for the future direction of the Company. Events Subsequent to year end On 12 September 2014, shareholders approved a capital reorganisation, resulting in each of the Company's existing ordinary shares being subdivided into one new Ordinary Share of 0.01p and one Deferred Share of 0.99p. Additionally, on 15 September 2014, the Company issued 175,000,000 new Ordinary Shares of 0.01p each for cash consideration of GBP210,000 (before expenses). The new shares will rank equally in all respects with the existing shares. On the same date, the Company adopted a new investing policy under AIM Rule 15 and there were a number of board changes as disclosed in the Report of the Directors. On 8 December 2014, the Company issued 375,000,000 new Ordinary Shares of 0.01p each for cash consideration of GBP1,500,000 (before expenses). The new shares will rank equally in all respects with the existing shares. Each new Ordinary Share carries a warrant which entitles the holder to subscribe for a further one new ordinary share in the Company at 0.4 pence per share up to 31 December 2015. On 18 December 2014, the Company announced that it has signed a Binding Term Sheet ("BTS") to acquire an initial 10% interest in Brazil Tungsten Holdings Limited ("BTHL") which owns a 25 year lease over (with the option to extend) the producing Bodó Tungsten Mine in Rio Grande do Norte, Brazil, by investing US$1 million in new capital in BTHL for the specific purposes of mine expansion. The Company will acquire the 10% interest by subscribing for new shares that represent a 10% shareholding in BTHL. The Company also has an exclusive option to increase its holding in BTHL to 20% within 60 days by investing a further US$1 million towards mine expansion, subject to certain conditions to be advised. Financial review Continuing operations The continuing operations of the Company relate to its investing activities and to its status as an AIM-listed public company. The Company incurred administrative expenses associated with operating as a public company and these totalled GBP127,000 for the year (2013: GBP190,000). On 19 March 2014, the Company acquired shares in another AIM listed public company, by way of the consideration for the disposal of our LabSkin(TM) and SYN1113 assets. These shares are accounted for as "Available-for-sale investments". At 31 July 2014, the Directors have assessed the valuation of those shares by reference to the quoted bid price and as a result have recorded an impairment loss on that investment of GBP72,000 (2013: not applicable) within the statement of profit or loss to reflect the fall in the published share price. Overall, the Company made a loss of GBP197,000 (2013: GBP182,000) from continuing operations. No income tax has arisen due to the losses sustained (2013: GBPnil). Discontinued operations During the year the Company ceased its scientific trading operations and shut down its trading site in Wetherby. All operational and administrative staff employed at that site were made redundant. The Company's LabSkin(TM) and SYN1113 intangible intellectual property assets, along with certain property, plant and equipment assets were sold to Venn Life Science Holdings plc on 19 March 2014. The financial results from that trade are presented within discontinued operations. The comparative figures for the year ended 31 July 2013 have been restated to enable comparison between the two years. In the year ended 31 July 2014, the trading operation generated revenues of GBP48,000 and sustained an overall loss for the year of GBP507,000 (2013: GBP825,000). Loss per ordinary share Basic and diluted loss per share arising from continuing operations has reduced from 0.10 pence for the year ended 31 July 2013, to 0.07 pence for the year ended 31 July 2014. Basic and diluted loss per share arising from discontinued operations has also reduced from 0.47 pence for the year ended 31 July 2013 to 0.29 pence for the year ended 31 July 2014. Outlook The Board considers that the current Investing Policy is in the best interests of the Company and its Shareholders as a whole. The Directors regularly assess investment opportunities for the Company in accordance with the investing policy which was adopted on 12 September 2014. Further capital has been raised by the Company which puts the Company in a good position to pursue new investment opportunities. The Board acknowledges this exciting period for the Company as it continues to evaluate and seek additional investments as opportunities arise. The Board is confident that we will be able to proceed with suitable investments for the Company over the course of the next year. The Board would like to take this opportunity to thank our shareholders for their continued support and I look forward to reporting further progress over the next period and beyond. David Lenigas - Executive Chairman ..."
5baggersrus: Y1 because a massive 175,000,000 shares are being 0.12p...yes 1/5th of the current share price....! ....can you subscribe at 0.12...NO ....can you buy at 0.6 and give subscribers a 500% profit....if you want ! 0.2p might be worth a punt at this stage imo
treacle32: Some v.nice buys including at premium too for 845,434 shares. Zilch downside from here imo - and more value and reflected in the share price should arise soon. Tom Bannatyne remains with a v.large holding at many multiples - always an added incentive. If rises tomorrow considering the premium buy then would complete double bottom formation.
treacle32: 2 types of deals in the offering...either of them should be transformational imo for the share price with the current mkt of just 0.40m and maybe equivalent to the value of an AIM listing. -- "Discussions ongoing regarding potential sale or licence of the Group's intellectual property assets".
theunluckyone: Temporarily Insane - Dont let her see the share price of these during next week then as I can see them being a bit volatile shall we say ! I already hold far more shares than my friend bought so there is no way that I am a deramper but I can see the share price spiking up to 5p or maybe even higher by Wednesday afternoon followed potentially by a fall on Thursday morning.I just cant believe that the company will announce a takeover bid on the last days trade before the long weekend and I can imagine the ultra short term holders dumping stock and the Market Makers driving the price down to trigger stops and getting some cheap stock back on their books.I would see this as a huge buying opportunity as I believe the share price would very quickly go back to earlier levels on the return to normal trading hours !!!
theunluckyone: 700K shares bought at or above full asking price and strangely no pushing of the share price by the market makers as would be expected to occur which causes the profit takers to pop up and nip the rise in the bud.I suppose this is down to our friends xcap for whom a rising share price is definitely not what they want with their short position.Of course the other market makers could and should follow the rules of supply and demand and push prices up instead of aiding and abetting their partners xcap !! Market Makers - I HATE THEM !!!!!!
greedfear: moosh2- I don't expect it to work out that way. A year ago a placing was done at 4p. The future of EVO looks very bright. The upcoming newsflow (and improved results because of that?) will be reflected in the share price imo. I can see EVO share price improvement of >100% short term. For me that's gain enough for the very near future. :)
Evocutis share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200121 07:49:07